8-K: Harmony Biosciences Secures Key Patent Settlement, Extending WAKIX Exclusivity to 2030

Harmony Biosciences Holdings, Inc. announced a settlement agreement with Lupin Limited, resolving patent infringement litigation and securing WAKIX's market exclusivity until at least January 2030.

Summary

• Harmony Biosciences Holdings, Inc. (HRMY) has reached a settlement agreement with Lupin Limited, resolving patent infringement litigation concerning Lupin's Abbreviated New Drug Application (ANDA) for a generic version of WAKIX (pitolisant hydrochloride).
• The agreement will lead to the dismissal of the litigation in the United States District Court for the District of Delaware.
• Lupin will receive a license to launch its generic WAKIX product no earlier than January 2030, or July 2030 if pediatric exclusivity applies, with potential for earlier launch under certain undisclosed circumstances.
• This settlement reinforces the validity and strength of Harmony's intellectual property portfolio for WAKIX, which is the first and only non-scheduled FDA-approved treatment for excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy and for EDS in pediatric patients 6 years of age and older with narcolepsy.
• Further bolstering Harmony's patent strength, on July 31, 2024, the U.S. Patent Office Patent Trial and Appeal Board declined, for the second time, to institute an Ex Parte Reexamination of Harmony's exclusively licensed polymorph patent for pitolisant hydrochloride, affirming its validity and enforceability.
• Harmony Biosciences is also advancing next-generation formulations of pitolisant with utility patents filed that could extend exclusivity to 2044.
• The company remains committed to defending its intellectual property and will continue litigating its consolidated patent infringement case against several other companies that have filed ANDAs seeking approval for generic versions of WAKIX.

Sentiment

Score: 8

Explanation: The sentiment is largely positive as the company successfully defended its key patent, securing several more years of market exclusivity for WAKIX. This removes a significant near-term overhang and validates its intellectual property. The negative aspect is the eventual generic entry, but the extended timeline is a clear win.

Positives

• The settlement agreement with Lupin Limited extends the market exclusivity for WAKIX until at least January 2030, providing a clear runway for continued revenue generation from its flagship product.
• The agreement reinforces the validity and strength of Harmony's intellectual property portfolio, which is crucial for protecting its innovative sleep/wake therapeutics.
• The U.S. Patent Office Patent Trial and Appeal Board's decision on July 31, 2024, to decline reexamination of the polymorph patent further affirms the validity and enforceability of Harmony's patent estate.
• Harmony is actively developing next-generation formulations of pitolisant, with utility patents filed that could potentially extend exclusivity to 2044, indicating a long-term strategic vision for the product.

Negatives

• The settlement ultimately allows for the entry of a generic version of WAKIX by Lupin Limited, which will introduce competition and impact Harmony's revenue stream starting in 2030 (or 2030 with pediatric exclusivity).

Risks

• Harmony Biosciences continues to face ongoing patent infringement litigation against several other companies that have filed Abbreviated New Drug Applications (ANDAs) seeking approval for generic versions of WAKIX, which could result in additional generic competition.
• The eventual launch of generic WAKIX by Lupin Limited and potentially other companies will lead to increased competition and could significantly impact Harmony's future net product revenue and market share.
• The effectiveness of WAKIX may be reduced by concomitant administration with strong CYP3A4 inducers or centrally acting H1 receptor antagonists.
• WAKIX may reduce the effectiveness of sensitive CYP3A4 substrates, including hormonal contraceptives, requiring patients to use alternative non-hormonal contraceptive methods.

Future Outlook

Harmony Biosciences is committed to vigorously defending its intellectual property and will continue litigating its consolidated patent infringement case against other companies. The company is also advancing next-generation formulations of pitolisant, with utility patents filed that could potentially extend exclusivity to 2044, aiming to address ongoing unmet medical needs in patients with narcolepsy and other central disorders of hypersomnolence.

Management Comments

• Harmony Biosciences stated that the settlement agreement reinforces the validity and strength of its intellectual property portfolio, which continues to protect its innovations in sleep/wake therapeutics.
• The company emphasized its commitment to vigorously defending its intellectual property and continuing litigation against other companies seeking to launch generic versions of WAKIX.

Industry Context

This patent settlement highlights the critical importance of intellectual property protection in the pharmaceutical industry, particularly for specialty and orphan drugs like WAKIX. Such agreements provide clarity on market exclusivity, allowing companies to continue investing in research and development while preparing for eventual generic competition. The extension of exclusivity for WAKIX until at least 2030 positions Harmony Biosciences favorably within the narcolepsy treatment market, providing a longer period to maximize revenue from its key product before generic entry.

Legal Proceedings

• Settlement agreement reached with Lupin Limited, resolving patent infringement litigation related to Lupin's Abbreviated New Drug Application (ANDA) for a generic version of WAKIX (pitolisant hydrochloride).
• Litigation in the United States District Court for the District of Delaware will be dismissed as part of the settlement.
• Harmony Biosciences continues to litigate its consolidated patent infringement case against several other companies that have filed ANDAs seeking approval for generic versions of WAKIX.
• On July 31, 2024, the U.S. Patent Office Patent Trial and Appeal Board declined, for the second time, to institute an Ex Parte Reexamination of Harmony's exclusively licensed polymorph patent for pitolisant hydrochloride, affirming its validity and enforceability.

Stakeholder Impact

• Shareholders: Benefit from extended market exclusivity for WAKIX, providing a longer period of protected revenue and reducing near-term uncertainty regarding generic competition.
• Patients: Continued availability of WAKIX as the primary treatment for narcolepsy without immediate generic disruption, ensuring access to an FDA-approved, non-scheduled treatment.
• Competitors: Lupin Limited gains a future license to launch a generic WAKIX, while other ANDA filers face ongoing litigation with Harmony Biosciences.

Next Steps

• Harmony Biosciences will continue litigating its consolidated patent infringement case against several other companies that have filed ANDAs seeking approval for generic versions of WAKIX.
• The company plans to continue advancing next-generation formulations of pitolisant, with utility patents filed that could potentially extend exclusivity to 2044.

Key Dates

Recommendation

Keywords

WAKIX, pitolisant, patent settlement, ANDA litigation, generic drug, narcolepsy, excessive daytime sleepiness, cataplexy, intellectual property, pharmaceuticals, Harmony Biosciences, Lupin Limited, FDA approved, orphan drug, neurological diseases